Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

scistats 319 posts  |  Last Activity: 15 hours ago Member since: Apr 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • In September 2014, Baxter Healthcare chose 650 East Kendall Street to be its flagship location in Cambridge, for a new global innovation and research and development (R&D) center at the site for its biopharmaceuticals business, which became a separate, independent global company known as Baxalta Incorporated. 650 East Kendal will house Baxalta’s CANCER THERAPY and business development operations. Baxalta will occupy 206,000 square feet. The building is owned by BioMed Realty Trust, Inc.

    Sentiment: Strong Buy

  • With its $32 billion purchase of Baxalta Inc. taking effect Friday, Shire PLC said it plans to retain and expand Baxalta’s drug research outpost in Kendall Square.

    The takeover, one of the largest life sciences deals of 2016, leave Shires — based in Ireland for tax purposes but run out of Lexington — with more than 3,000 workers in Massachusetts, making it the state’s second largest biopharma employer, after Sanofi Genzyme.

    Shire chief executive Flemming Ornskov said in an interview that his company plans to expand Baxalta’s 400-person research center at 650 E. Kendall St. by 100 to 200 jobs. He said he would also keep an office at the research center as a window on the entrepreneurial activity in the area.

    “We’re increasing our activity in the Massachusetts area,” said Ornskov, a Danish doctor-turned-dealmaker who has become one of the industry’s most aggressive acquirers in recent years. “This is de facto one of the world’s premier hubs for biotech research. It’s great for Shire now to be in the flow of a place that’s one of the world’s centers for innovation.”

    Baxalta, formed last summer when health care conglomerate Baxter International spun off its biosciences business, is focusing on hemophilia, immunology, and cancer drug development in Cambridge. The company opened the research center in Kendall Square last December.

    Sentiment: Strong Buy

  • Reply to

    Shire spotlights Boston-area base, cancer R&D

    by scistats Jun 8, 2016 9:18 PM
    scistats scistats Jun 8, 2016 9:19 PM Flag

    by John Carroll | Jun 3, 2016 9:20am

    Sentiment: Strong Buy

  • There were times during Shire’s slow-motion takeover of Baxalta that journalists joked that they had forgotten that the M&A effort was still on. But on Friday the two companies reached the end of a long set of negotiations, formally completing a $32 billion merger that creates a big biopharma company with 22,000 staffers worldwide focused primarily on rare diseases.

    The next big step will be slicing out the $500 million in “synergies” that were promised with the deal--which presumably includes axing an uncertain number of jobs in the process. But Shire settled at least one mystery about its R&D structure on the first day. Shire CEO Flemming Ornskov told The Boston Globe that he plans to keep Baxalta’s new research outpost on Kendall Square, the heart of the regional biotech hub, even looking to add anywhere from 100 to 200 researchers in the process.

    “We’re increasing our activity in the Massachusetts area,” Ornskov told the friendly hometown newspaper. “This is de facto one of the world’s premier hubs for biotech research. It’s great for Shire now to be in the flow of a place that’s one of the world’s centers for innovation.”

    Shire may be based in Dublin for tax purposes, but under Ornskov the company has been concentrating heavily around the campus in Lexington, MA. Last year Shire ripped up much of its organization in Pennsylvania as Ornskov accelerated that process, moving hundreds of jobs to Massachusetts.

    Ornskov still has a long way to go to deliver on a promise to increase revenue to more than $20 billion a year. One aspect of that campaign was highlighted in the merger release today, as Shire heralded the growing cancer drug franchise it acquired in the deal.

    Sentiment: Strong Buy

  • MERRIMACK HEALTHCARE SOLUTIONS is hiring

    Merrimack Oncology Partner - Kansas City (Kansas, W. Missouri)
    Merrimack Oncology Partner - Little Rock (Arkansas, Oklahoma, Louisiana)
    Merrimack Oncology Partner - Miami, FL (Orlando, Boca Raton, Fort Lauderdale, Miami)
    Merrimack Oncology Partner – San Francisco, CA
    Merrimack Oncology Partner - Southeast (Baltimore/DC/Northern Virginia)
    Merrimack Oncology Partner - Upstate New York (Albany, Syracuse, Rochester)
    Product Availability and Access Coordinator

    Sentiment: Strong Buy

  • At these levels, I concur with Zacks.

    "Cambridge, MA-based Merrimack Pharmaceuticals, Inc. MACK has transitioned from a development-stage company to a commercial-stage company following the FDA approval of cancer treatment, Onivyde, in Oct 2015. Onivyde is off to an encouraging start and its addition to the National Comprehensive Cancer Network (NCCN) 2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option should also boost sales. This Zacks Rank #2 (Buy) stock is working on expanding Onivyde’s label and has several interesting candidates in its pipeline for different types of cancer."

    Sentiment: Strong Buy

  • scistats scistats Jun 6, 2016 8:54 PM Flag

    Dave was sacked for not buying MACK when he had the chance.
    He will be missed.

    Sentiment: Strong Buy

  • MM-151 shows positive clinical activity in phase 1 study of multiple solid tumor types

    MM-151 is an oligoclonal therapeutic consisting of a mixture of 3 fully human monoclonal antibodies designed to bind and inhibit signaling of the epidermal growth factor receptor (EGFR). EGFR-mediated signaling promotes the growth and survival of cancer cells and has long been recognized as an important drug target in several types of cancer, including colon, lung, breast, pancreatic, and head and neck cancers. MM-151 is a mixture of 3 independent antibodies, binding to 3 nonoverlapping sites on EGFR to maximize inhibition of ligand-dependent and independent signaling.

    Sentiment: Strong Buy

  • scistats scistats Jun 6, 2016 10:11 AM Flag

    Ask and ye shall receive.

    Sentiment: Strong Buy

  • Reply to

    New HERMIONE publication.

    by scistats Jun 5, 2016 3:49 PM
    scistats scistats Jun 5, 2016 3:50 PM Flag

    Figure 2 is cool.

    Sentiment: Strong Buy

  • BMC Cancer. 2016 Jun 3;16(1):352.

    HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

    Sentiment: Strong Buy

  • Reply to

    The Guardian Article

    by pylesm Jun 4, 2016 1:25 AM
    scistats scistats Jun 4, 2016 9:36 AM Flag

    Now, if we put those two in an antibody decorated liposome for increased targeting and concentration, I wonder how much better would it be?

    Sentiment: Strong Buy

  • Reply to

    The Guardian Article

    by pylesm Jun 4, 2016 1:25 AM
    scistats scistats Jun 4, 2016 9:16 AM Flag

    The study enrolled patients following pancreatic cancer surgery.

    "Although most people diagnosed with pancreatic cancer are not candidates for surgery, the findings show that those who can have surgery "have a fighting chance of surviving this cancer with the combination of two commonly used chemotherapies," said John Neoptolemos, the study's lead author of the University of Liverpool in Britain."

    Sentiment: Strong Buy

  • scistats scistats Jun 3, 2016 9:56 PM Flag

    Dollar cost average your Roth contributions.
    90 percent Vanguard S&P 500, 10 percent gold ETF.

    Sentiment: Strong Buy

  • Title Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2016
    Date 20/06/2016 - 23/06/2016
    Location European Medicines Agency, London, UK
    Summary The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.

    Sentiment: Strong Buy

  • Big Pharma battle for $20 billion annual cited by CEO Gil Van Bokkelen Ph.D. as largest indication ever.
    About to begin.
    What's happening over in Mesoblast land?

    Sentiment: Strong Buy

  • scistats scistats Jun 3, 2016 7:51 AM Flag

    The fight for the billions is going to get rank.
    Hold on!

    Sentiment: Strong Buy

  • scistats scistats Jun 3, 2016 7:50 AM Flag

    Proven allogeneic cells are not under the radar any more.
    Hold on! so4UvO-g6Kk

    Sentiment: Strong Buy

  • Reply to

    Stanford stem cell results

    by wood111111 Jun 2, 2016 8:10 PM
    scistats scistats Jun 3, 2016 7:43 AM Flag

    Multistem is primarily targeting the spleen response in acute stroke cases within 36 hours of the stroke to prevent brain damage BEFORE it occurs using IV infusion.

    SanBio is doing damage repair in chronic stroke cases months later by injecting MSCs directly onto the brain. Multistem can do this too, in fact some small molecules may be crossing the blood brain barrier after infusion for acute stroke, so the spleen may only be part of the story. Regardless, there is no reason why Mulstiem cannot be injected directly on the brain as well for chronic stroke. Multistem can also be transfected with Notch or something similar.

    Sentiment: Strong Buy

  • Reply to

    Stanford stem cell results

    by wood111111 Jun 2, 2016 8:10 PM
    scistats scistats Jun 3, 2016 7:36 AM Flag

    No 48 hr window!
    No 48 hr window!
    Remember, the change to include the 48 window is why the first phase 2 failed and Chugai left.
    It is 36 hr or less for Multistem, and I think closer to 24 hr is ideal.

    Sentiment: Strong Buy

GERN
2.640.00(0.00%)Jun 29 4:00 PMEDT